Phase 3 eXalt3 study shows significantly longer progression-free survival 0 08.08.2020 07:00 Eurekalert.org Patients with non-small cell lung cancer (NSCLC) carrying anaplastic lymphoma kinase (ALK) gene alterations who received ensartinib experienced substantially longer progression-free survival than a matched group of patients who received crizotinib. Moscow.media Частные объявления сегодня Rss.plus Все новости за 24 часа
